Funding

Caldera Therapeutics

United States · Biotech

Develops bispecific antibody CLD-423 for inflammatory bowel disease

Visit calderatx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A1$37.5MJanus Henderson Investors — Role not disclosedLAV — Role not disclosedOmega Funds — Role not disclosedvenBio — Role not disclosedWellington Management — Role not disclosed

Investors

Janus Henderson InvestorsSeries A1LAVSeries A1Omega FundsSeries A1venBioSeries A1Wellington ManagementSeries A1

Coverage

Jan 14, 2026Caldera Therapeutics · Series A1

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcescalderatx.com ↗